Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Different mode of arrestin-3 binding at the human Y1 and Y2 receptor.

Wanka L, Babilon S, Kaiser A, Mörl K, Beck-Sickinger AG.

Cell Signal. 2018 Jun 23;50:58-71. doi: 10.1016/j.cellsig.2018.06.010. [Epub ahead of print]

PMID:
29944985
2.

G Protein Preassembly Rescues Efficacy of W6.48 Toggle Mutations in Neuropeptide Y2 Receptor.

Kaiser A, Hempel C, Wanka L, Schubert M, Hamm HE, Beck-Sickinger AG.

Mol Pharmacol. 2018 Apr;93(4):387-401. doi: 10.1124/mol.117.110544. Epub 2018 Feb 7.

PMID:
29436493
3.

C-terminal motif of human neuropeptide Y4 receptor determines internalization and arrestin recruitment.

Wanka L, Babilon S, Burkert K, Mörl K, Gurevich VV, Beck-Sickinger AG.

Cell Signal. 2017 Jan;29:233-239. doi: 10.1016/j.cellsig.2016.11.003. Epub 2016 Nov 3.

4.

A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways.

Hu J, Stern M, Gimenez LE, Wanka L, Zhu L, Rossi M, Meister J, Inoue A, Beck-Sickinger AG, Gurevich VV, Wess J.

J Biol Chem. 2016 Apr 8;291(15):7809-20. doi: 10.1074/jbc.M115.702282. Epub 2016 Feb 5.

5.

Peptide modifications differentially alter G protein-coupled receptor internalization and signaling bias.

Mäde V, Babilon S, Jolly N, Wanka L, Bellmann-Sickert K, Diaz Gimenez LE, Mörl K, Cox HM, Gurevich VV, Beck-Sickinger AG.

Angew Chem Int Ed Engl. 2014 Sep 15;53(38):10067-71. doi: 10.1002/anie.201403750. Epub 2014 Jul 25.

6.

Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes.

Gimenez LE, Babilon S, Wanka L, Beck-Sickinger AG, Gurevich VV.

Cell Signal. 2014 Jul;26(7):1523-31. doi: 10.1016/j.cellsig.2014.03.019. Epub 2014 Mar 29.

7.

Lipophilic oligopeptides for chemo- and enantioselective acyl transfer reactions onto alcohols.

Müller CE, Zell D, Hrdina R, Wende RC, Wanka L, Schuler SM, Schreiner PR.

J Org Chem. 2013 Sep 6;78(17):8465-84. doi: 10.1021/jo401195c. Epub 2013 Aug 14.

PMID:
23875609
8.

The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Wanka L, Iqbal K, Schreiner PR.

Chem Rev. 2013 May 8;113(5):3516-604. doi: 10.1021/cr100264t. Epub 2013 Feb 25. Review. No abstract available.

9.

Enantiomerically enriched trans-diols from alkenes in one pot: a multicatalyst approach.

Hrdina R, Müller CE, Wende RC, Wanka L, Schreiner PR.

Chem Commun (Camb). 2012 Mar 4;48(19):2498-500. doi: 10.1039/c2cc17435a. Epub 2012 Jan 30.

PMID:
22286064
10.

Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice.

Blanchard J, Wanka L, Tung YC, Cárdenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I.

Acta Neuropathol. 2010 Nov;120(5):605-21. doi: 10.1007/s00401-010-0734-6. Epub 2010 Aug 10.

PMID:
20697724
11.

Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice.

Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I.

FEBS Lett. 2010 Aug 4;584(15):3359-65. doi: 10.1016/j.febslet.2010.06.025. Epub 2010 Jun 30.

12.

Enantioselective kinetic resolution of trans-cycloalkane-1,2-diols.

Müller CE, Wanka L, Jewell K, Schreiner PR.

Angew Chem Int Ed Engl. 2008;47(33):6180-3. doi: 10.1002/anie.200800641. No abstract available.

PMID:
18618558

Supplemental Content

Support Center